Oncology Expert Insights

Hirsch Matani, MD, Elizabeth Zhang-Velten, MD, PhD, and Binh T. Ngo, MD, discuss radiation and multidisciplinary approaches in skin cancer.

Navigating Radiation, Systemic Therapy, and Multidisciplinary Care in Skin Cancer: With Hirsch Matani, MD; Elizabeth Zhang-Velten, MD, PhD; and Binh T. Ngo, MD

ByHirsch Matani, MD,Elizabeth Zhang-Velten, MD, PhD,Binh T. Ngo, MD

June 1st 2026

Hirsch Matani, MD, Elizabeth Zhang-Velten, MD, PhD, and Binh T. Ngo, MD, discuss radiation and multidisciplinary approaches in skin cancer.

Archana Jadhav, MD; Monica Peravali, MD; and Anthony Chi, MD; faculty at the Mid-Atlantic Permanente Medical Group

In-House Molecular Testing in NSCLC Improves Turnaround Time, Tissue Stewardship, and Multidisciplinary Coordination: Featuring Anthony Chi, MD; Monica Peravali, MD; and Archana Jadhav, MD

ByMonica Peravali, MD,Archana Jadhav, MD,Anthony Chi, MD

May 28th 2026

Drs Chi, Peravali, and Jadhav discuss the practical advantages and clinical implications of implementing in-house NGS testing for patients with NSCLC.

Jacob Sands, MD, associate chief of the Lowe Center for Thoracic Oncology, Oncology Medical Director of the International Patient Center, and physician at Dana-Farber Cancer Institute, as well as an assistant professor at Harvard Medical School

Emerging Targets, Second-Line Standards, and Molecular Subtyping Signal a New Era in SCLC Care: With Jacob Sands, MD

ByJacob Sands, MD

May 26th 2026

Dr Sands discusses the rapidly evolving treatment landscape for SCLC.

TKIs Continue to Move Forward and Expand Their Potential in CML: With Michael J. Mauro, MD

ByMichael J. Mauro, MD

May 22nd 2026

Michael J. Mauro, MD, discusses his approach to TKI use in chronic myeloid leukemia and how new FDA approvals inform his practice.

Pedram Razavi, MD, PhD, breast medical oncologist, director, Liquid Biopsy & Genomics, Memorial Sloan Kettering Cancer Center; Dara S. Ross, MD, associate attending pathologist, Memorial Sloan Kettering Cancer Center

Evolving ESR1 Mutation Testing Directions Complicate the Future of Metastatic Breast Cancer Management: With Pedram Razavi, MD, PhD; and Dara S. Ross, MD

ByPedram Razavi, MD, PhD,Dara S. Ross, MD

May 20th 2026

Drs Razavi and Ross note the evolution of ESR1 mutation–directed breast cancer management, including the role of genomic testing at metastatic recurrence.

Biomarker-Directed Therapies Move the GI Oncology Paradigm Beyond a One-Size-Fits-All Approach: With Michael J. Pishvaian, MD, PhD

ByMike J. Pishvaian, MD, PhD

May 8th 2026

Michael J. Pishvaian, MD, PhD discusses how biomarker-directed strategies, including HER2, CLDN18.2, and KRAS inhibition, are transforming GI cancer care.

FES-PET/CT Reshapes Treatment Planning in Lobular Breast Cancer and Beyond: With Megan Kruse, MD

ByMegan Kruse, MD

April 30th 2026

Megan Kruse, MD, discusses the evolving role of FES-PET/CT in breast cancer, particularly invasive lobular carcinoma.

Alissa Cooper, MD, a physician at Dana-Farber Cancer Institute and an instructor in medicine at Harvard Medical School

Treatment Advances in Relapsed SCLC Introduce New Options and Clinical Workflows: With Alissa Cooper, MD

ByAlissa J. Cooper, MD

April 30th 2026

Dr Cooper discusses recent advances that have reshaped the treatment paradigm for small cell lung cancer, particularly in the relapsed setting.

Quinto Gesiotto, MD, discusses optimal ponatinib dosing strategies and evolving TKI sequencing considerations in chronic myeloid leukemia.

Optimizing TKI Sequencing and Ponatinib Dosing Strategies in CML: With Quinto Gesiotto, MD

ByQuinto Gesiotto, MD

April 1st 2026

Quinto Gesiotto, MD, discusses optimal ponatinib dosing strategies and evolving TKI sequencing considerations in chronic myeloid leukemia.

Ticiana Leal, MD, professor and director of the Thoracic Medical Oncology Program in the Department of Hematology and Medical Oncology at Emory University School of Medicine, as well as the medical director of the Clinical Trials Office at Winship Cancer Institute

Variability and Innovation in Small Cell Lung Cancer Care: With Ticiana Leal, MD

ByTiciana A. Leal, MD

March 31st 2026

Dr Leal discusses variability in community practice and evolving treatment strategies for patients with small cell lung cancer.

Misty D. Shields, MD, PhD, translational medical oncologist at Indiana University Health in Indianapolis

Community Practice Perspectives: Overcoming Barriers in Small Cell Lung Cancer Care: With Misty D. Shields, MD, PhD

ByMisty D. Shields, MD, PhD

March 30th 2026

Dr Shields discusses the realities of treating patients with SCLC in the community setting and how emerging therapies are shaping care delivery.

John Marshall, MD, chief, Hematology and Oncology, professor, medicine and oncology, director, Otto J Ruesch Center for the Cure of Gastrointestinal Cancers, Georgetown Lombardi Comprehensive Cancer Center; Christopher Lieu, MD, professor, medicine, associate director, Clinical Research, co-director, Gastrointestinal Medical Oncology, University of Colorado Anschutz and the University of Colorado Cancer Center

New Trials and Targeted Approaches Advance the Precision of GI Cancer Care: With John Marshall, MD; and Christopher Lieu, MD

ByJohn L. Marshall, MD,Christopher Lieu, MD

March 27th 2026

Drs Marshall and Lieu discuss the clinical relevance of KRAS G12C and pan-RAS inhibitors in the management of pancreatic and colorectal cancers.

Real-World Analyses Help Make Sense of Multiple Approved CAR T-Cell Therapies for ALL: With Jae Park, MD

ByJae Park, MD

March 25th 2026

Jae Park, MD, discusses recent developments for obe-cel and brexu-cel in acute lymphoblastic leukemia.

Real-World Data Support ctDNA-Guided Treatment Strategies in FGFR2-Altered Cholangiocarcinoma: With Marina Baretti, MD

ByMarina Baretti, MD

March 25th 2026

Marina Baretti, MD, discussed the potential utilization of tissue-free ctDNA monitoring for early recurrence detection and treatment monitoring in CCA.

ctDNA Testing At Progression May Help Detect Resistance and Guide Sequencing in GIST: With Drs Jonathan Trent, MD, PhD, and Neeta Somaiah, MD

ByJonathan C. Trent, MD,Neeta Somaiah, MD

March 20th 2026

Jonathan Trent, MD, PhD, and Neeta Somaiah, MD, discuss the importance of identifying genomic drivers and resistance patterns for therapy selection in GIST.

ASH Guidelines Provide Key Recommendations for AYA Acute Lymphoblastic Leukemia Management: With Wendy Stock, MD

ByWendy Stock, MD

March 20th 2026

Colin Vale, MD, assistant professor, Department of Hematology and Medical Oncology, Emory University School of Medicine

Novel Treatment Combinations for B-ALL May Help Patients Safely Achieve Remission: With Colin Vale, MD

ByColin Vale, MD

March 18th 2026

Dr Vale discusses data from a phase 2 trial evaluating blinatumomab plus ponatinib in Philadelphia chromosome–positive B-cell acute lymphoblastic leukemia.

Gregory J. Tiesi, MD, FACS, FSSO, medical director, Hepatobiliary Surgery, Hackensack Meridian Jersey Shore University Medical Center; Anthony Scholer, MD, FACS, FSSO, surgical oncologist, hepatobiliary surgery, Hackensack Meridian Medical Group and Jersey Shore University Medical Center; Benjamin Jon Golas, MD, FACS, regional chief, Surgical Oncology, Hackensack Meridian Health’s Central Region, surgical director, Oncology Services, Jersey Shore University Medical Center, vice chair, Surgery, Jersey Shore University Medical Center Cancer Surgery, associate professor, surgery, Hackensack Meridian School of Medicine; Eric Pletcher, MD, surgeon, Complex General Surgical Oncology, Hackensack Meridian JFK University Medical Center

Trans-Arterial Micro-Perfusion Could Boost Systemic Chemotherapy Efficacy in Unresectable Pancreatic Cancer: With Gregory J. Tiesi, MD, FACS, FSSO; Anthony Scholer, MD, FACS, FSSO; and Eric Pletcher, MD

ByGregory J. Tiesi, MD, FACS, FSSO,Anthony Scholer, MD, FACS, FSSO,Benjamin Jon Golas, MD, FACS,Eric Pletcher, MD

March 13th 2026

Drs Tiesi, Scholer, and Pletcher discuss the growing role for TAMP as a regional therapy strategy for patients with locally advanced PDAC.

Exploring CAR T in Solid Tumors, Clinical Trials, and Cancer Incidence Questions

BySonali Smith, MD

March 11th 2026

Sonali Smith, MD, discusses CAR-T cell therapies moving into solid tumors, the role of clinical trials in hematologic oncology, and the rising incidence of certain cancers in young adults.

Incorporating TROP2-Targeted ADCs Into Lung Cancer Treatment Algorithms: With Eric K. Singhi, MD

ByEric K. Singhi, MD

March 5th 2026

Eric K. Singhi, MD, discusses where TROP2-directed ADCs like datopotamab deruxtecan and sacituzumab tirumotecan may fit in evolving treatment algorithms in lung cancer.

Integrating Novel Targets and Translational Insights Into SCLC Practice: With Anne Chiang, MD, PhD

ByAnne Chiang, MD, PhD, Yale Cancer Center

February 27th 2026

Anne Chiang, MD, PhD, discusses the rapidly evolving treatment landscape in SCLC and what this new era of innovation means for patients.

Megan Kruse, MD, breast medical oncologist, Cleveland Clinic; Sophia O’Brien, MD, assistant professor, clinical radiology, Divisions of Nuclear Medicine and Breast Imaging, associate program director, Diagnostic Radiology Residency, Penn Medicine

Breast Imaging Advances Emphasize the Importance of Patient-Focused Nuclear Medicine Collaboration: With Megan Kruse, MD; and Sophia O’Brien, MD

ByMegan Kruse, MD,Sophia R. O'Brien, MD

February 27th 2026

Drs Kruse and O’Brien highlight the various roles of imaging modalities in breast cancer diagnosis and treatment decision-making.

Six-Year CheckMate 9LA Data Reinforce Durable Survival in Metastatic NSCLC: With David Carbone, MD, PhD

ByDavid Carbone, MD, PhD

February 26th 2026

David Carbone, MD, PhD, discusses the 6-year data from the phase 3 CheckMate 9LA trial (NCT03215706).

Deb Schrag, MD, MPH, medical oncologist, Memorial Sloan Kettering Cancer Center

Innovation, Equity, and the Future of Oncology: World Cancer Day Spotlight With Deb Schrag, MD, MPH

ByDeb Schrag, MD, MPH

February 4th 2026

Dr Schrag weighed in on where oncology stands today and previewed the goals she hopes to advance during her tenure as ASCO President in 2027-2028.

Eric Whitman, MD, medical director, oncology service line, Atlantic Health System; Vishal Patel, MD, FAAD, FACMS, associate professor, dermatology and medicine, GW School of Medicine & Health Sciences, director, Cutaneous Oncology Program, GW Cancer Center

Multidisciplinary Teams Optimize Surgical and Therapeutic Roles in Advanced CSCC Care: With Eric Whitman, MD; and Vishal Patel, MD, FAAD, FACMS

ByEric Whitman, MD,Vishal A. Patel, MD, FAAD, FACMS

January 30th 2026

Drs Whitman and Patel discuss the evolving treatment paradigm for patients with CSCC, emphasizing the role of neoadjuvant and adjuvant immunotherapies.

Komal Jhaveri, MD, FACP, breast medical oncologist, Memorial Sloan Kettering Cancer Center

ASCENT-07 Trial Propels Further Questions About the Role of Earlier-Line ADCs in HR+ Metastatic Breast Cancer: With Komal Jhaveri, MD, FACP

ByKomal Jhaveri, MD, FACP

January 30th 2026

Dr Jhaveri discusses the evaluation of sacituzumab govitecan earlier in the HR-positive, HER2-negative metastatic breast cancer treatment paradigm.

Subcutaneous Isatuximab via On-Body Injector Has Noninferior Efficacy vs IV Delivery in Myeloma: With Sikander Ailawadhi, MD; and Beth Faiman, CNP, PhD

ByBeth M. Faiman, PhD, MS, APN-BC, BMTCN, AOCN, FAAN, FAPO,Sikander Ailawadhi, MD

January 30th 2026

Sikander Ailawadhi, MD, and Beth Faiman, CNP, PhD, discuss the ongoing development of subcutaneous isatuximab administration via an on-body injector for patients with multiple myeloma.

Aditya Bardia, MD, MPH, FASCO, director, Translational Research Integration, member, Signal Transduction and Therapeutics, UCLA Health Jonsson Comprehensive Cancer Center

ELEGANT Trial Seeks to Expand Treatment Options for ER+, HER2-Negative Early Breast Cancer: With Aditya Bardia, MD, MPH, FASCO

ByAditya Bardia, MD, MPH, FASCO

January 29th 2026

Dr Bardia discusses the ELEGANT study of elacestrant in estrogen receptor–positive, HER2-negative early breast cancer at high risk of disease recurrence.

Novel Targeted Agents Are Poised to Influence the MPN Treatment Paradigm: With John O. Mascarenhas, MD

ByJohn O. Mascarenhas, MD

January 29th 2026

John O. Mascarenhas, MD, details the investigation of novel targeted therapies in patients with myeloproliferative neoplasms.

Joanna M. Rhodes, MD, MSCE, director, Lymphoma, systems head, Lymphoma, Rutgers Cancer Institute of New Jersey and RWJBarnabas Health; Krish Patel, MD, director, Lymphoma Research, executive chair, Lymphoma Research Executive Committee, Sarah Cannon Research Institute

CLL Treatment Paradigm Shifts With Evolving Treatment Sequencing and BTK Inhibition: With Joanna M. Rhodes, MD, MSCE; and Krish Patel, MD

ByJoanna M. Rhodes, MD, MSCE,Krish Patel, MD

December 31st 2025

Drs Rhodes and Patel highlight how the chronic lymphocytic leukemia treatment paradigm continues to evolve with advances in targeted therapy.

Oncology Expert Insights

Navigating Radiation, Systemic Therapy, and Multidisciplinary Care in Skin Cancer: With Hirsch Matani, MD; Elizabeth Zhang-Velten, MD, PhD; and Binh T. Ngo, MD

In-House Molecular Testing in NSCLC Improves Turnaround Time, Tissue Stewardship, and Multidisciplinary Coordination: Featuring Anthony Chi, MD; Monica Peravali, MD; and Archana Jadhav, MD

Emerging Targets, Second-Line Standards, and Molecular Subtyping Signal a New Era in SCLC Care: With Jacob Sands, MD

TKIs Continue to Move Forward and Expand Their Potential in CML: With Michael J. Mauro, MD

Evolving ESR1 Mutation Testing Directions Complicate the Future of Metastatic Breast Cancer Management: With Pedram Razavi, MD, PhD; and Dara S. Ross, MD

Biomarker-Directed Therapies Move the GI Oncology Paradigm Beyond a One-Size-Fits-All Approach: With Michael J. Pishvaian, MD, PhD

FES-PET/CT Reshapes Treatment Planning in Lobular Breast Cancer and Beyond: With Megan Kruse, MD

Treatment Advances in Relapsed SCLC Introduce New Options and Clinical Workflows: With Alissa Cooper, MD

Optimizing TKI Sequencing and Ponatinib Dosing Strategies in CML: With Quinto Gesiotto, MD

Variability and Innovation in Small Cell Lung Cancer Care: With Ticiana Leal, MD

Community Practice Perspectives: Overcoming Barriers in Small Cell Lung Cancer Care: With Misty D. Shields, MD, PhD

New Trials and Targeted Approaches Advance the Precision of GI Cancer Care: With John Marshall, MD; and Christopher Lieu, MD

Real-World Analyses Help Make Sense of Multiple Approved CAR T-Cell Therapies for ALL: With Jae Park, MD

Real-World Data Support ctDNA-Guided Treatment Strategies in FGFR2-Altered Cholangiocarcinoma: With Marina Baretti, MD

ctDNA Testing At Progression May Help Detect Resistance and Guide Sequencing in GIST: With Drs Jonathan Trent, MD, PhD, and Neeta Somaiah, MD

ASH Guidelines Provide Key Recommendations for AYA Acute Lymphoblastic Leukemia Management: With Wendy Stock, MD

Novel Treatment Combinations for B-ALL May Help Patients Safely Achieve Remission: With Colin Vale, MD

Trans-Arterial Micro-Perfusion Could Boost Systemic Chemotherapy Efficacy in Unresectable Pancreatic Cancer: With Gregory J. Tiesi, MD, FACS, FSSO; Anthony Scholer, MD, FACS, FSSO; and Eric Pletcher, MD

Exploring CAR T in Solid Tumors, Clinical Trials, and Cancer Incidence Questions

Incorporating TROP2-Targeted ADCs Into Lung Cancer Treatment Algorithms: With Eric K. Singhi, MD

Integrating Novel Targets and Translational Insights Into SCLC Practice: With Anne Chiang, MD, PhD

Breast Imaging Advances Emphasize the Importance of Patient-Focused Nuclear Medicine Collaboration: With Megan Kruse, MD; and Sophia O’Brien, MD

Six-Year CheckMate 9LA Data Reinforce Durable Survival in Metastatic NSCLC: With David Carbone, MD, PhD

Innovation, Equity, and the Future of Oncology: World Cancer Day Spotlight With Deb Schrag, MD, MPH

Multidisciplinary Teams Optimize Surgical and Therapeutic Roles in Advanced CSCC Care: With Eric Whitman, MD; and Vishal Patel, MD, FAAD, FACMS

ASCENT-07 Trial Propels Further Questions About the Role of Earlier-Line ADCs in HR+ Metastatic Breast Cancer: With Komal Jhaveri, MD, FACP

Subcutaneous Isatuximab via On-Body Injector Has Noninferior Efficacy vs IV Delivery in Myeloma: With Sikander Ailawadhi, MD; and Beth Faiman, CNP, PhD

ELEGANT Trial Seeks to Expand Treatment Options for ER+, HER2-Negative Early Breast Cancer: With Aditya Bardia, MD, MPH, FASCO

Novel Targeted Agents Are Poised to Influence the MPN Treatment Paradigm: With John O. Mascarenhas, MD

CLL Treatment Paradigm Shifts With Evolving Treatment Sequencing and BTK Inhibition: With Joanna M. Rhodes, MD, MSCE; and Krish Patel, MD

Trending on OncLive

Targeted Therapies, ADCs, and Oral SERD Combos Expand Treatment Possibilities Across Breast Cancer Settings

Head and Neck Oncologists Highlight Practice-Informing Research From ASCO 2026

Dr Galsky on the Current Roles of Biomarkers in Bladder Cancer

Sonrotoclax Plus Zanubrutinib Yields High Undetectable MRD Rates in Treatment-Naive CLL/SLL

FDA Grants Priority Review to Adjuvant Atezolizumab Plus Chemotherapy for Stage III dMMR Colon Cancer